Solanezumab: Did Aβ ‘Reflux’ From Blood Confound Target Engagement in CSF? After Solanezumab: Where Should Alzheimer’s Research Go? At an expert meeting convened by Alzheimer’s Research UK, scientists from Eli Lilly shared Aβ biomarker data from the Exped
Next-Generation Tau PET Tracers Strut Their Stuff Are CSF Assays Finally Ready for Prime Time? ApoE and Tau: Unholy Alliance Spawns Neurodegeneration New Evidence Confirms TREM2 Binds Aβ, Drives Protective Response Location, Conformation, Decoration: Tau
Protein Liquid-Liquid Phase Transitions: The Science Is About to Gel Confused about protein liquid-liquid phase transitions? You are not alone. Researchers working in this emerging field gathered in Leuven in early May to make sense of the latest data lin
Microglial Regulation and Function Scrutinized at Heidelberg Meeting A New Explanation for Dendritic Tau: It’s Made There Alzheimer’s Proteomics Treasure Trove? sAPP Binds GABA Receptor, and More News on APP At Heidelberg meeting, scientists shared and de
Finally, a Blood Test for Alzheimer’s? In Clinical Use, Amyloid Scans Change Two-Thirds of Treatment Plans Searching for New AD Risk Variants? Move Beyond GWAS Monomeric Seeds and Oligomeric Clouds—Proteopathy News from AAIC Planning the First Primary Pre
10th CTAD: Finally, Alzheimer’s Field Is Serious About Prevention Trials At CTAD, Tau PET Emerges as Favored Outcome Biomarker for Trials Automated CSF Tests: Check. Blood Tests: In the Works Cognitive Testing Is Getting Faster and Better Don’t Be an Enro
Tau Snapshots from Neuroscience 2017 Disturbed Sleep Exerts Toll on Memory and Neurodegeneration Gut Microbiome May Modify Neurodegeneration Is There No End to Tau’s Toxic Tricks? This year’s annual meeting drew more than 23,000 scientists and featured 1,
After Plasma Aβ, Now Plasma P-Tau181 Shows Promise To Block Tau’s Proteopathic Spread, Antibody Must Attack its Mid-Region DIAN and ADNI Data Say Familial and Sporadic AD Converge News From the PET Front: Early Amyloid Networks and Tau Mystery Alzheimer’s
As RNA Therapies Come of Age, Efficacy Remains Weak At AAN, Sights Set on Antisense Therapies for Diseases of the Brain New Alzheimer’s and Parkinson’s Immunotherapy Data at AAN Will RNA molecules that bump up or tamp down gene expression live up to their
A Delicate Frontier: Human Microglia Focus of Attention at Keystone TREM2: Diehard Microglial Supporter, Consequences Be DAMed ApoE Has Hand in Alzheimer’s Beyond Aβ, Beyond the Brain Synaptic Tau Clangs the Dinner Bell for Hungry Microglia VCAM1: Gateway
BAN2401 Removes Brain Amyloid, Possibly Slows Cognitive Decline On Target: Crenezumab Reduces Aβ Oligomers in CSF PET Ligand Lights Up AAIC, May Detect Synapse Loss in AD Could Better Blood Pressure Management Preserve Cognition? Focused Ultrasound Breach
Alzheimer’s Researchers Seek Advice on How to Include African-Americans Do African-Americans Have More, or Different, Alzheimer’s Disease? Too Little Data to Tell Is Alzheimer’s more common, or different, in black Americans? Or do cerebrovascular risk fac
Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition Second Look at BAN2401 Data Still Positive, Despite Snafu Blood Tests for Amyloid Step Out at CTAD It’s Official: Tau PET Sees Tangles, and Staging Tangles Predicts Decline Amyloid PET Aids Di